Immuneel Therapeutics (Immuneel) has entered into a collaboration and licensing agreement with Hospital Clinic de Barcelona (HCB) and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) for treatment of B cell malignancies.
The collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, Immuneel acquired the exclusive rights to develop and commercialise autologous ARI-0001 – a CD19 Chimeric antigen receptor (CAR) T cell therapy, in India.
This agreement puts Immuneel in the pursuit of offering accessible and affordable CAR Ts to patients in India through registration clinical trials and its investments in further process optimisation.
Kiran Mazumdar Shaw, Co-founder, Immuneel, said, “This partnership with HCB & IDIBAPS is pathbreaking and heralds the advent of life saving CAR T therapy for patients in India. Immuneel is committed to providing affordable access to this therapy at facilities housed at the Mazumdar Shaw Cancer Centre. I would